FIELD: medicine.
SUBSTANCE: invention refers to medicine, pharmacology and biology. What is presented is a complex of tris-(2-hydroxyethyl)amine and bis-(2-methylphenoxyacetate)zinc [cinkatran or citrimin] of formula: (HOCH2CH2)3N·Zn(OOCCH2OC6H4CH3-2)2 as an agent reducing cholesterol esterase activity.
EFFECT: reducing cholesterol esterase activity.
2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USING PROTATRAN 4-CHLOR-2-METHYLPHENOXYACETATE (CHLORCRESACIN) FOR ARREST OF CHOLESTEROLESTERASE ACTIVITY | 2014 |
|
RU2563831C1 |
| AGENT TO DECREASE CHOLESTEROL ESTERASE ACTIVITY | 2010 |
|
RU2444357C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND BIS-(2-METHYLPHENOXY-ACETATE) ZINC (ZINCATRAN) FOR REDUCING TOTAL ACTIVITY OF ACIDIC PHOSPHOLIPASE A1 | 2014 |
|
RU2545888C1 |
| METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
| 1-HYDROXYGERMATRANE USAGE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2742972C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXYACETATE) (CINKATRAN) AS AGENT SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) MONONUCLEAR PHOSPHOLIPASE A2 | 2014 |
|
RU2546537C1 |
| USE OF 1-(GERMATRAN-1-YL)-1-HYDROXYETHYLAMINE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2746321C1 |
| METHOD OF ATHEROGENESIS CORRECTION IN EXPERIMENT USING 1-(GERMATRAN-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2741906C1 |
| AGENT MODULATING ACID PHOSPHOLIPASE A1 ACTIVITY | 2010 |
|
RU2445087C1 |
| APPLICATION OF PROTATRAN 4-CHLORO-2-METHYLPHENOXYACETATE FOR EXHAUSTING OF MONONUCLEAR CELLS BASIC (ALKALINE) PHOSPHOLIPASE a2 TOTAL ACTIVITY | 2016 |
|
RU2619860C1 |
